retatrutide type 2 diabetes phase 2 trial Reta clinical data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in 3 trials for metabolic health — targeting GLP-1, GIP Phase 2 trial results demonstrate
Pay in 4 interest-free payments of $6.66 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6

























